IDEXX Laboratories (IDXX) 10-Q 29 Apr 16 2016 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2016	Apr. 20, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q1
Entity Registrant Name	IDEXX LABORATORIES INC /DE
Entity Central Index Key	874,716
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		89,531,171

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Current Assets:
Cash and cash equivalents	$ 132,953	$ 128,994
Marketable securities	217,617	213,591
Accounts receivable, net of reserves of $5,100 in 2016 and $5,128 in 2015	212,072	188,318
Inventories	183,759	188,833
Deferred income tax assets		39,829
Other current assets	62,605	62,069
Total current assets	809,006	821,634
Long-Term Assets:
Property and equipment, net	343,010	333,026
Goodwill	181,941	178,934
Intangible assets, net	53,257	55,909
Other long-term assets	91,433	85,490
Total long-term assets	669,641	653,359
TOTAL ASSETS	1,478,647	1,474,993
Current Liabilities:
Accounts payable	52,458	52,648
Accrued liabilities	178,267	205,530
Line of credit	622,000	573,000
Current portion of deferred revenue	25,943	25,583
Total current liabilities	878,668	856,761
Long-Term Liabilities:
Deferred income tax liabilities	15,597	49,389
Long-term debt	600,021	597,085
Long-term deferred revenue, net of current portion	27,787	27,055
Other long-term liabilities	30,361	28,698
Total long-term liabilities	673,766	702,227
Total liabilities	$ 1,552,434	$ 1,558,988
Commitments and Contingencies (Note 13)
Stockholders’ Deficit:
Common stock, $0.10 par value: Authorized: 120,000 shares; Issued: 102,546 and 102,237 shares in 2016 and 2015, respectively	$ 10,255	$ 10,258
Additional paid-in capital	952,943	940,534
Deferred stock units: Outstanding: 240 units in both 2016 and 2015	5,432	5,409
Retained earnings	364,375	318,356
Accumulated other comprehensive loss	(37,515)	(42,265)
Treasury stock, at cost: 13,000 and 12,242 shares in 2016 and 2015, respectively	(1,369,412)	(1,316,417)
Total IDEXX Laboratories, Inc. stockholders’ deficit	(73,922)	(84,125)
Noncontrolling interest	135	130
Total stockholders’ deficit	(73,787)	(83,995)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$ 1,478,647	$ 1,474,993

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Condensed Consolidated Balance Sheets [Abstract]
Accounts receivable, reserves	$ 5,100	$ 5,128
Common stock, par value	$ 0.10	$ 0.10
Common stock, shares authorized	120,000,000	120,000,000
Common stock, shares issued	102,546,000	102,237,000
Deferred stock units, outstanding	240,000	240,000
Treasury stock, shares	13,000,000	12,242,000

Condensed Consolidated Statemen

Condensed Consolidated Statements Of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Revenue:
Product revenue	$ 249,065	$ 232,104
Service revenue	168,485	150,373
Total revenue	417,550	382,477
Cost of Revenue:
Cost of product revenue	97,631	83,370
Cost of service revenue	92,382	83,563
Total cost of revenue	190,013	166,933
Gross profit	227,537	215,544
Expenses:
Sales and marketing	79,829	75,136
General and administrative	49,295	42,599
Research and development	24,620	25,006
Income from operations	73,793	72,803
Interest expense	(8,304)	(6,304)
Interest income	820	425
Income before provision for income taxes	66,309	66,924
Provision for income taxes	20,284	20,346
Net income	46,025	46,578
Less: Net income (loss) attributable to noncontrolling interest	6	(16)
Net income attributable to IDEXX Laboratories, Inc. stockholders	$ 46,019	$ 46,594
Earnings per Share:
Basic	$ 0.51	$ 0.49
Diluted	$ 0.51	$ 0.49
Weighted Average Shares Outstanding:
Basic	89,924	94,280
Diluted	90,838	95,521

Condensed Consolidated Stateme5

Condensed Consolidated Statements Of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Condensed Consolidated Statements Of Comprehensive Income [Abstract]
Net income	$ 46,025	$ 46,578
Other comprehensive income, net of tax:
Foreign currency translation adjustments	6,016	(20,232)
Unrealized gain on net investment hedge	2,224
Unrealized gain on investments, net of tax expense of $70 in 2016 and $19 in 2015	205	33
Unrealized gain (loss) on derivative instruments:
Unrealized gain (loss), net of tax expense (benefit) of ($1,443) in 2016 and $3,082 in 2015	(3,266)	7,185
Less: reclassification adjustment for gains included in net income, net of tax expense of $170 in 2016 and $1,253 in 2015	(429)	(2,964)
Unrealized gain (loss) on derivative instruments	(3,695)	4,221
Other comprehensive gain (loss), net of tax	4,750	(15,978)
Comprehensive income	50,775	30,600
Less: comprehensive income (loss) attributable to noncontrolling interest	6	(16)
Comprehensive income attributable to IDEXX Laboratories, Inc.	$ 50,769	$ 30,616

Condensed Consolidated Stateme6

Condensed Consolidated Statements Of Comprehensive Income (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Condensed Consolidated Statements Of Comprehensive Income [Abstract]
Unrealized gain (loss) on investments, tax expense (benefit)	$ 70	$ 19
Unrealized gain, tax expense	(1,443)	3,082
Reclassification adjustment for gains included in net income, tax expense	$ 170	$ 1,253

Condensed Consolidated Stateme7

Condensed Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash Flows from Operating Activities:
Net income	$ 46,025	$ 46,578
Adjustments to reconcile net income to net cash provided (used) by operating activities:
Depreciation and amortization	18,546	16,154
Impairment charge	1,110
Benefit of deferred income taxes	2,520	565
Share-based compensation expense	4,922	4,652
Other	586	625
Tax benefit from share-based compensation arrangements	(2,063)	(7,713)
Changes in assets and liabilities:
Accounts receivable	(21,504)	(51,438)
Inventories	1,764	(10,142)
Other assets and liabilities	(27,516)	(10,746)
Accounts payable	(1,801)	(4,332)
Deferred revenue	637	1,153
Net cash provided (used) by operating activities	23,226	(14,644)
Cash Flows from Investing Activities:
Purchases of property and equipment	(21,906)	(23,017)
Purchase of marketable securities	(72,079)	(140,448)
Proceeds from the sale and maturities of marketable securities	70,186	3,228
Acquisitions of a businesses, net of cash acquired		(383)
Net cash used by investing activities	(23,799)	(160,620)
Cash Flows from Financing Activities:
Borrowings on revolving credit facilities, net	49,000	500
Debt issue costs	(57)	(90)
Issuance of long term debt		150,000
Repurchases of common stock	(53,480)	(133,647)
Proceeds from exercises of stock options and employee stock purchase plans	5,760	12,325
Payment of acquisition-related contingent consideration	(2,084)
Tax benefit from share-based compensation arrangements	2,063	7,713
Net cash provided by financing activities	1,202	36,801
Net effect of changes in exchange rates on cash	3,330	(1,913)
Net increase (decrease) in cash and cash equivalents	3,959	(140,376)
Cash and cash equivalents at beginning of period	128,994	322,536
Cash and cash equivalents at end of period	$ 132,953	$ 182,160

Basis Of Presentation And Princ

Basis Of Presentation And Principles Of Consolidation	3 Months Ended
	Mar. 31, 2016
Basis Of Presentation And Principles Of Consolidation [Abstract]
Basis Of Presentation And Principles Of Consolidation	NOTE 1. BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION The accompanying condensed consolidated financial statements of IDEXX Laboratories, Inc. and its subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the requirements of Regulation S-X, Rule 10-01 for financial statements required to be filed as a part of this Quarterly Report on Form 10-Q. Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q to "IDEXX," the "Company," "we," "our" or "us" refer to IDEXX Laboratories, Inc. and its subsidiaries. The accompanying condensed consolidated financial statements include the accounts of IDEXX Laboratories, Inc. and our wholly-owned and majority-owned subsidiaries. We do not have any variable interest entities for which we are the primary beneficiary. All intercompany transactions and balances have been eliminated in consolidation.  The accompanying condensed consolidated financial statements reflect, in the opinion of our management, all adjustments necessary for a fair statement of our financial position and results of operations. All such adjustments are of a recurring nature. The consolidated balance sheet data at December 31, 201 5 was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. The results of operations for the three months ended March 31 , 201 6 are not necessarily indicative of the results to be expected for the full year or any future period. These condensed consolidated financial statements should be read in conjunction with this Quarterly Report on Form 10- Q for the quarter ended March 31 , 201 6 and our Annual Report on Form 10-K for the year ended December 31, 201 5 (the “2015 Annual Report”) filed with the U.S. Securities and Exchange Commission (“SEC”).  Stock Split  On May 6, 2015, we announced a two-for-one split of our outstanding shares of common stock which was effected through a stock dividend that was paid through the issuance of treasury shares. The stock split entitled each stockholder of record at the close of business on May 18, 2015 to receive one additional share of common stock for each outstanding share of common stock held. The additional shares of our common stock paid pursuant to the stock split were distributed by the Company’s transfer agent on June 15, 2015. All share and per share amounts in the condensed consolidated balance sheets, condensed consolidated statement of operations and notes to the condensed consolidated financial statements for the three months ended March 31, 2015 retroactively reflect the effect of the stock split unless otherwise noted.  Reclassifications  Certain prior year amounts have been reclassified to conform with the c urrent year presentation. R eclassifications had no material impact on previously reported results of operations, financial position or cash flows. 

Accounting Policies

Accounting Policies	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Accounting Policies	Note 2. ACCOUNTING POLICIES  Significant Accounting Policies  T he significant accounting policies used in preparation of these condensed consolidated financial statements for the three months ended March 31 , 201 6 are consistent with those discussed in Note 2 to the consolidated financial statements in our 201 5 Annual Report, except as noted below.  New Accounting Pronouncements Adopted  Deferred Income Taxes  During the first quarter of 2016, the C ompany early adopted Financial Accounting Standards Board (“ FASB ”) amendments which require us to classify all deferred tax assets and liabilities as noncurrent within our condensed consolidated balance sheet. In accordance with the FASB’s permitted transition guidance, we applied this guidance prospectively and did not revise our prior period balance sheet presentation for the effects of this amendment. These amendments did not have a material impact on our financial statements.  Deferred Financing Costs  Effective January 1, 2016, the C ompany adopted FASB amendments that require debt issuance costs related to a recognized debt liability be presented within the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. This reclassification of the presentation of deferred financing costs did not have a material impact on other long-term assets or long-term debt amounts reported in our March 31, 2016 condensed consolidated balance sheet and additionall y would not have a material impact on such amounts reported in a prior period. As such, these amendments have been reflected prospectively in 2016; prior period amounts have not been revised for the effects of this amendment.  The FASB confirmed in August 2015 that the aforementioned amendments did not address the presentation or subsequent measurement of debt issuance costs related to line-of-credit arrangements. For line-of-credit arrangements, borrowers have the option of presenting debt issuance costs as an asset which is subsequently amortized ratably over the term of the line-of-credit arrangement, regardless of whether there are any related outstanding borrowings. As such, we continue to present deferred financing costs associated with our unsecured revolving credit facility within other long-term assets in the accompanying condensed consolidated balance sheets. Following recognition within the condensed consolidated balance sheets, all deferred financing costs are amortized to interest expense using the effective interest rate method over the term of the related debt agreement. These amendments did not have a material impact on our financial statements.  Additional Pronou n cements  During the three months ended March 31, 2016, the adoption of other effective FASB amendments addressing measurement-period adjustments for business combinations, accounting for cloud computing arrangements that include a software license, and to the fair value hierarchy of investments measured at net asset value did not have a material impact on our financial statements.  New Accounting Pronouncements Not Yet Adopted  In May 2014, the FASB issued an amendment which will replace most of the existing revenue recognition guidance within U.S. GAAP. The core principle of this guidance is that an entity should recognize revenue for the transfer of goods or services to customers in an amount that it expects to be entitled to receive for those goods or services. In doing so, companies will be required to make certain judgments and estimates, including identifying contract performance obligations, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price among separate performance obligations. Additionally, the amendment requires disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, significant judgments reached in the application of the guidance and assets recognized from the costs to obtain or fulfill a contract. In July 2015, the FASB voted to defer the effective date of the amendment to apply to public business entities for annual and interim periods ending after December 15, 2017. The amendment allows for two methods of adoption: a full retrospective method or a modified retrospective approach with the cumulative effect recognized at the date of initial application. We are in the process of determining the method of adoption and the impact of this amendment on our consolidated financial statements.  In August 2014, the FASB issued an amendment that requires management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. The amendments in this update provide guidance about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern for one year after the date that the financial statements are issued and to provide related footnote disclosures. In doing so, the amendments should reduce diversity in the timing and content of footnote disclosures. The amendments in this update apply to all entities and are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. This amendment is not expected to have a material impact on our financial statements.  In February 2015, the FASB issued amendments which change the analysis that a reporting entity must perform to determine whether it should consolidate certain types of legal entities, placing more emphasis on risk of loss when determining a controlling financial interest. The amendments in this update apply to all entities and are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. This amendment is not expected to have a material impact on our financial statements.  In July 2015, the FASB issued amendments which simplify the existing guidance which requires entities to subsequently measure inventory at the lower of cost or market value. Under the amendments, an entity should measure inventory valued using a first-in, first-out or average cost method at the lower of cost or net realizable value, which is defined as the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. This update is effective for public business entities during fiscal years beginning after December 15, 2016. Early adoption is permitted. This amendment is not expected to have a material impact on our financial statements.  In February 2016, the FAS B issued amendments to increase transparency and comparability among organizations’ leasing arrangements. The principal difference from previous guidance is that effective upon adoption, the lease assets and lease liabilities arising from operating leases will be recognized in the statement of financial position. For public business en tities, the amendments in this u pdate are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. In transition, we are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach, including the option to utilize a number of practical expedients. We are i n the process of determining the impact of this amendment on our consolidated financial statements.  In March 2016, the FAS B issued amendments which simplify several aspects of the accounting for share-based payment transactions, including income tax consequences, recognition of stock compensation award forfeitures, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The most significant change resulting from these amendments is recording all the tax effects related to share-based payments at settlement through the income statement. Under existing guidance, tax benefits in excess of compensation costs (“windfalls”) are recorded in equity. Similar ly , tax deficiencies below compensation costs (“shortfalls”) are recorded in equity to the extent of previous windfalls, while shortfalls in excess of this are recorded to the income statement. For public business entities, this update is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted for any entity in any interim or annual period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. An entity that elects early adoption must adopt all of the amendments in the same period. We are in the process of determining the method of adoption and the impact of this amendment on our consolidated financial statements. 

Share-Based Compensation

Share-Based Compensation	3 Months Ended
	Mar. 31, 2016
Share-Based Compensation [Abstract]
Share-Based Compensation	NOTE 3 . SHARE-BASED COMPENSATION The fair value of options, restricted stock units, deferred stock units and employee stock purchase rights awarded during the three months ended March 31, 2016 and 2015 totaled $24.0 million and $22.0 million, respectively. T he total unrecognized compensation expense, net of estimated forfeitures, for unvested share-based compensatio n awards outstanding at March 31, 2016 was $54.7 million, which will be recognized over a weighted average period of approximately 2. 3 yea rs. We determine the assumptions used in the valuation of option awards as of the date of grant. Differences in the expected stock price volatility, expected term or risk-free interest rate may necessitate distinct valuation assumptions at each grant date. As such, we may use different assumptions for options granted throughout the year. Option awards are granted with an exercise price equal to the closing market price of our common stock at the date of grant. We have never paid any cash dividends on our common stock, and we have no intention to pay such a dividend at this time; therefore, we assume that no dividends will be paid over the expected terms of option awards.  The weighted averages of the valuation assumptions used to determine the fair value of each option award on the date of grant and the weighted average estimated fair values were as follows:   For the Three Months Ended  March 31,  2016 2015   Expected stock price volatility 25 % 23 %  Expected term, in years 5.7 5.6  Risk-free interest rate 1.2 % 1.5 %   Weighted average fair value of options granted $ 17.54 $ 19.99 

Marketable Securities

Marketable Securities	3 Months Ended
	Mar. 31, 2016
Marketable Securities [Abstract]
Marketable Securities	Note 4 . marketable securities  The amortized cost and fair value of marketable securities were as follows ( in thousands ):    As of March 31, 2016 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value   Corporate bonds $ 152,383 $ 85 $ (90) $ 152,378  Asset backed securities 24,430 37 - 24,467  U.S. government bonds 17,057 11 - 17,068  Commercial paper 9,840 - - 9,840  Certificates of deposit 8,600 - - 8,600  Agency bonds 2,401 - - 2,401  International government bonds 1,457 - (1) 1,456  Municipal bonds 1,400 7 - 1,407  Total marketable securities $ 217,568 $ 140 $ (91) $ 217,617   As of December 31, 2015 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value   Corporate bonds $ 177,810 $ 24 $ (221) $ 177,613  U.S. government bonds 12,881 - (10) 12,871  Agency bonds 12,068 - (3) 12,065  Certificates of deposit 3,500 - - 3,500  Commercial paper 3,491 - - 3,491  International government bonds 1,462 - (3) 1,459  Municipal bonds 1,400 - (1) 1,399  Treasury bill 1,192 1 - 1,193  Total marketable securities $ 213,804 $ 25 $ (238) $ 213,591  As of March 31, 2016, unrealized losses on marketable securities that have been in a continuous loss position for more than twelve months were not material. Our portfolio of marketable securities had an average AA- credit rating as of March 31, 2016. There were no marketable securities that we consider to be other-than-temporarily impaired as of March 31, 2016.  Remaining contractual maturities of marketable securities were as follows ( in thousands ):     As of March 31, 2016 Amortized Cost Fair Value   Due in one year or less $ 162,177 $ 162,198  Due after one year through three years 55,391 55,419  $ 217,568 $ 217,617 

Inventories

Inventories	3 Months Ended
	Mar. 31, 2016
Inventories [Abstract]
Inventories	Note 5 . Inventories Inventories, which are stated at the lower of cost (first-in, first-out) or market, include material, conversion costs and inbound freight charges. The components of inventories were as follows (in thousands) :    March 31, December 31,  2016 2015   Raw materials $ 32,029 $ 31,184  Work-in-process 19,439 18,698  Finished goods 132,291 138,951  Inventories $ 183,759 $ 188,833 

Goodwill and Intangible Assets,

Goodwill and Intangible Assets, Net	3 Months Ended
	Mar. 31, 2016
Goodwill and Intangible Assets, Net [Abstract]
Goodwill And Intangible Assets, Net	Note 6 . Goodwill and Intangible Assets, NET The increase in goodwill during the three months ended March 31, 2016 resulted from changes in foreign currency exchange rates. The decrease in intangible assets other than goodwill during the three months ended March 31, 2016 resulted primarily from the continued amortization of our intangible assets and a n impairment related to our OPTI line of business, partly offset by changes in foreign currency exchange rates.  During the first quarter of 2016, management reviewed our OPTI Medical product offerings . As a result of this review, we discontinued our product development activities in the human point-of-care medical diagnostics market during March 2016 and instead will focus our commercial efforts in this market on supporting our latest generation OPTI CCA-TS2 Blood Gas and Electrolyte Analyzer.  We assess ed the realizability of the related tangible and intangible assets a s a result of the afo rementioned change in strategy and determined the expected future cash flows were less than the carrying value of the asset group . As a result, we recorded a non - cash intangible asset impairment of $1.1 million within our condensed consolidated statement of operations for the three months ended March 31, 2016. 

Other Current and Long-Term Ass

Other Current and Long-Term Assets	3 Months Ended
	Mar. 31, 2016
Other Current and Long-Term Assets [Abstract]
Other Current and Long-Term Assets	NOTE 7 . Other current and long-term ASSETS  Other current assets consisted of the following (in thousands) :    March 31, December 31,  2016 2015   Prepaid expenses $ 23,970 $ 27,244  Taxes receivable 13,219 11,792  Customer acquisition costs, net 16,573 16,412  Other assets 8,843 6,621  Other current assets $ 62,605 $ 62,069  Other long-term assets consisted of the following (in thousands) :    March 31, December 31,  2016 2015   Investment in long-term product supply arrangements $ 12,305 $ 12,165  Customer acquisition costs, net 45,663 43,570  Other assets 33,465 29,755  Other long-term assets $ 91,433 $ 85,490 

Accrued Liabilities

Accrued Liabilities	3 Months Ended
	Mar. 31, 2016
Accrued Liabilities [Abstract]
Accrued Liabilities	Note 8 . Accrued liabilities Accrued liabilities consisted of the following (in thousands) :    March 31, December 31,  2016 2015   Accrued expenses $ 62,649 $ 65,665  Accrued employee compensation and related expenses 46,688 77,027  Accrued taxes 24,815 18,963  Accrued customer programs 44,115 43,875  Accrued liabilities $ 178,267 $ 205,530 

Repurchases Of Common Stock

Repurchases Of Common Stock	3 Months Ended
	Mar. 31, 2016
Repurchases Of Common Stock [Abstract]
Repurchases Of Common Stock	Note 9 . Repurchases of common STOCK  We primarily acquire shares by means of repurchases in the open market. However, we also acquire shares tha t are surrendered by employees in payment for the minimum required withholding taxes due on the vesting of restricted stock units and the settlement of deferred stock units, otherwise referred to herein as employee surrenders.  We issue shares of treasury stock upon the vesting of certain restricted stock units and upon the exercise of certain stock options. The number of shares of treasury st ock issued during both the three months ended March 31, 2016 and 201 5 was not material.  The following is a summary of our open market common stock repurchases , reported on a trade date basis, and shares acquired through employee surrender for the three months ended March 31 , 201 6 and 201 5 (in thousands, except per share amounts) :    March 31, March 31,  2016 2015   Shares repurchased (1) 708 1,718  Shares acquired through employee surrender (1) 52 61  Total shares repurchased (1) 760 1,779   Cost of shares repurchased $ 49,715 $ 133,647  Cost of employee surrenders 3,529 4,866  Total cost of shares repurchased $ 53,244 $ 138,513   Average cost per share $ 70.06 $ 77.85 _____________ (1) Shares repurchased and acquired through employee surrender for payment of minimum required withholding taxes on and before June 15, 2015 and the associated average cost per share have been adjusted to reflect the June 15, 2015 two -for-one stock split. Actual shares repurchased were approximately 890,000 for the three months ended March 31, 2015 . 

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2016
Income Taxes [Abstract]
Income Taxes	Note 10 . Income Taxes Our effective income tax rate was 30.6% and 30.4% for the t hree months ended March 31, 2016 and 2015 , respectively . The increase in our effective rate for the three months ended March 31, 2016 as compared to the same period of the prior year was related to lower relative earnings subject to international tax rates that are lower than domestic tax rates, including the impact of foreign currency exchange rates, partly offset by the benefit of the U.S. research and development (“R&D”) tax credit. There was no available U.S. R&D tax credit during the period ending March 31, 2015 because the credit had not yet been extended. In December 2015, the U.S. R&D tax credit was permanently extended with retroactive application to January 1, 2015. 

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income	3 Months Ended
	Mar. 31, 2016
Accumulated Other Comprehensive Income [Abstract]
Accumulated Other Comprehensive Income	Note 1 1 . ACCUMULATED OTHER Comprehensive Income The changes in accumulated other comprehensive income (“ AOCI ”), net of tax, for the three months ended March 31 , 201 6 consisted of the following (in thousands) :   For the Three Months Ended March 31, 2016 Unrealized Gain (Loss) on Investments, Net of Tax Unrealized Gain (Loss) on Derivative Instruments, Net of Tax Unrealized Gain on Net Investment Hedge, Net of Tax Cumulative Translation Adjustment Total   Balance as of December 31, 2015 $ (225) $ 2,217 $ 1,894 $ (46,151) $ (42,265)  Other comprehensive (loss) income before reclassifications 205 (3,266) 2,224 6,016 5,179  Gains reclassified from accumulated other comprehensive income - (429) - - (429)  Balance as of March 31, 2016 $ (20) $ (1,478) $ 4,118 $ (40,135) $ (37,515)         The following is a summary of reclassifications out of AOCI for the three months ended March 31 , 201 6 and 201 5 (in thousands) :     Details about AOCI Components Affected Line Item in the Statement of Operations Amounts Reclassified from AOCI For the Three Months Ended March 31,  2016 2015  Gains (losses) on derivative instruments classified as cash flow hedges included in net income:  Foreign currency exchange contracts Cost of revenue $ 809 $ 4,479  Interest rate swaps Interest expense (210) (262)  Total gains before tax 599 4,217  Tax expense 170 1,253  Gains, net of tax $ 429 $ 2,964  

Earnings Per Share

Earnings Per Share	3 Months Ended
	Mar. 31, 2016
Earnings Per Share [Abstract]
Earnings Per Share	 Note 1 2 . Earnings per Share Basic earnings per share is computed by dividing net income attributable to IDEXX Laboratories, Inc. stockholders by the weighted average number of shares of common stock and vested deferred stock units outstanding during the year. The computation of diluted earnings per share is similar to the computation of basic earnings per share, except that the denominator is increased for the assumed exercise of dilutive options and assumed issuance of unvested restricted stock units and unvested deferred stock units using the treasury stock method unless the effect is anti-dilutive. The treasury stock method assumes that proceeds, including cash received from the exercise of employee stock options, the total unrecognized compensation expense for unvested share-based compensation awards and the excess tax benefits resulting from share-based compensation tax deductions in excess of the related expense recognized for financial reporting purposes, would be used to purchase our common stock at the average market price during the period. Vested deferred stock units outstanding are included in shares outstanding for basic and diluted earnings per share because the associated shares of our common stock are issuable for no cash consideration, the number of shares of our common stock to be issued is fixed and issuance is not contingent. See Note 4 to the consolidated financial statements in our 201 5 Annual Report for additional information regarding deferred stock units.  The following is a reconciliation of weighted average shares outstanding for basic and diluted earnings per share for the three months ended March 31 , 201 6 and 201 5 (in thousands) :   For the Three Months Ended  March 31,  2016 2015   Shares outstanding for basic earnings per share 89,924 94,280   Shares outstanding for diluted earnings per share:  Shares outstanding for basic earnings per share 89,924 94,280  Dilutive effect of share-based payment awards 914 1,241  90,838 95,521 C ertain options to acquire shares and restricted stock units have been excluded from the calculation of shares outstanding for diluted earnings per share because they were anti-dilutive. The following table presents information concerning those anti-dilutive options and restricted stock units for the three months ended March 3 1 , 201 6 and 2015 (in thousands ):   For the Three Months Ended  March 31,  2016 2015   Weighted average number of shares underlying anti-dilutive options 1,044 363   Weighted average number of shares underlying anti-dilutive restricted stock units - 67 

Commitments, Contingencies And

Commitments, Contingencies And Guarantees	3 Months Ended
	Mar. 31, 2016
Commitments, Contingencies And Guarantees [Abstract]
Commitments, Contingencies And Guarantees	Note 13 . Commitments, Contingencies and Guarantees Significant commitments, contingencies and guarantees at March 3 1 , 201 6 are consistent with those discussed in Note 1 4 to the consolidated financial statements in our 201 5 Annual Report .

Segment Reporting

Segment Reporting	3 Months Ended
	Mar. 31, 2016
Segment Reporting [Abstract]
Segment Reporting	Note 1 4 . Segment Reporting Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision-maker (“CODM”) , or decision-making group, in deciding how to allocate resources and in assessing performance. Our CODM is our Chief Executive Officer. Our reportable segments include diagnostic and information technology-based products and services for the veterinary market, which we refer to as the Companion Animal Group (“CAG”), water quality produc ts (“Water”) and diagnostic product s and services for livestock and poultry health and to ensure the quality and safety of milk and food, which we refer to as Livestock, Poultry and Dairy (“LPD”). Our Other operating segment combines and presents products for the human point-of-care medical diagnostics market with our pharmaceutical product line and our out-licensing arrangements because they do not meet the quantitative or qualitative thresholds for reportable segments.  Certain costs are not allocated to our operating segments and are instead reported under the caption “Unallocated Amounts”. These costs include costs that do not align with one of our existing operating segments or are cost prohibitive to allocate, which primarily consist of our R&D function, regional or country expenses, certain foreign currency revaluation gains and losses on monetary balances in currencies other than our subsidiaries’ functional currency and unusual items. Corporate support function costs (such as information technology, facilities, human resources, finance and legal), health benefits and incentive compensation are charged to our business segments at pre-determined budgeted amounts or rates. Differences from these pre-determined budgeted amounts or rates are captured within Unallocated Amounts.  Effective January 1, 2016, we modified our management reporting to the CODM to provide a more comprehensive view of the performance of our operating segments by including the capitalization of variances between standard and actual manufacturing costs, which adjusts the timing of cost recognition from when the variance is created to the period in which the related inventory is sold. Prior to January 1, 2016, the capitalization and subsequent recognition of these variances were not allocated to our operating segments and were instead reported under the caption “Unallocated Amounts”.  The segment gross profit and income (loss) from operations within this report for the quarter ended March 31, 2015 has been retrospectively revised to reflect the aforementioned changes to our segment performance metrics.  The following is a summary of segment p erformance for the three months ended March 3 1 , 201 6 and 201 5 (in thousands) :     For the Three Months Ended March 31,  CAG Water LPD Other Unallocated Amounts Consolidated Total  2016  Revenue $ 357,639 $ 23,552 $ 30,856 $ 5,503 $ - $ 417,550   Income (loss) from operations $ 61,378 $ 9,679 $ 4,570 $ (837) $ (997) $ 73,793  Interest expense, net (7,484)  Income before provision for income taxes 66,309  Provision for income taxes 20,284  Net income 46,025  Less: Net income attributable to noncontrolling interest 6  Net income attributable to IDEXX Laboratories, Inc. stockholders $ 46,019   2015  Revenue $ 324,531 $ 21,698 $ 31,270 $ 4,978 $ - $ 382,477   Income (loss) from operations $ 53,518 $ 9,361 $ 6,956 $ (322) $ 3,290 $ 72,803  Interest expense, net (5,879)  Income before provision for income taxes 66,924  Provision for income taxes 20,346  Net income 46,578  Less: Net loss attributable to noncontrolling interest (16)  Net income attributable to IDEXX Laboratories, Inc. stockholders $ 46,594    The following is a summary of revenue by product and servic e category for the three months ended March 3 1 , 201 6 and 201 5 ( in thousands ):   For the Three Months Ended  March 31,  2016 2015  CAG segment revenue:  CAG Diagnostics recurring revenue: $ 305,510 $ 278,766  IDEXX VetLab ® consumables 107,959 98,392  IDEXX VetLab service and accessories 13,757 13,530  Rapid assay products 43,086 43,637  Reference laboratory diagnostic and consulting services 140,708 123,207  CAG Diagnostics capital - instruments 22,974 20,113  Customer information management and diagnostic imaging systems 29,155 25,652  CAG segment revenue 357,639 324,531   Water segment revenue 23,552 21,698  LPD segment revenue 30,856 31,270  Other segment revenue 5,503 4,978  Total revenue $ 417,550 $ 382,477 

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2016
Fair Value Measurements [Abstract]
Fair Value Measurements	Note 15 . FAIR VALUE MEASUREMENTS U.S. GAAP defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. U.S. GAAP requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. The Company has certain financial assets and liabilities that are measured at fair value on a recurring basis, certain nonfinancial assets and liabilities that may be measured at fair value on a nonrecurring basis and certain financial assets and liabilities that are not measured at fair value in our condensed consolidated balance sheets but for which we disclose the fair value. The fair value disclosures of these assets and liabilities are based on a three-level hierarchy, which is defined as follows : Level 1 Quoted prices in active markets for identical assets or liabilities that the entity can access at the measurement date. Level 2 Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. We did not have any transfers between Level 1 and Level 2 or transfers in or out of Level 3 of the fair value hierarchy during the three months ended March 31, 2016.  Our marketable debt securities are initially valued at the transaction price and are subsequently remeasured to fair value as of the balance sheet date utilizing third- party pricing services. The pricing services utilize industry standard valuation models, i ncluding both income and market- based approaches and observable market inputs to determine value. Observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers and other industry and economic events. We validate t he prices provided by our third- party pricing services by obtaining independent market values from other pricing sources and analyzing pricing data in certain instances.  Our foreign currency exchange contracts and interest rate swap agreements are measured at fair value on a recurring basis in our accompanying condensed consolidated balance sheets. We measure the fair value of our foreign currency exchange contracts classified as derivative instruments using an income approach, based on prevailing market forward rates less the contract rate multiplied by the notional amount. The product of this calculation is then adjusted for counterparty risk. We measure the fair value of our interest rate swaps classified as derivative instruments using an income approach, utilizing a discounted cash flow analysis based on the terms of the contract and the interest rate curve adjusted for counterparty risk. The amount outstanding under our unsecured revolving credit facility (“Credit Facility”) and long-term debt are measured at carrying value in our accompanying condensed consolidated balance sheets though we disclose the fair value of these financial instruments. We determine the fair value of the amount outstanding under our Credit Facility and long-term debt using an income approach, utilizing a discounted cash flow analysis based on current market interest rates for debt issues with similar remaining years to maturity, adjusted for applicable credit risk. Our Credit Facility and l ong-term debt are valued using L evel 2 inputs. The estimated fair value of o ur Credit Facility approximates its carrying value. The estimated fair value and carrying value of our long-term debt were $612.0 million and $ 600.6 million , respectively, as of March 31, 2016 and $593.7 million and $597.1 million , respectively, as of December 31, 201 5 .  The following tables set forth our assets and liabilities that were measured at fair val ue on a recurring basis at March 3 1 , 201 6 and at December 31, 201 5 by level within the fair value hierarchy (in thousands) :   Quoted Prices Significant  in Active Other Significant  Markets for Observable Unobservable  Identical Assets Inputs Inputs Balance at  As of March 31, 2016 (Level 1) (Level 2) (Level 3) March 31, 2016   Assets  Money market funds (1) $ 9,213 $ - $ - $ 9,213  Commercial paper (1) - 2,299 - 2,299   Marketable Securities  Corporate bonds - 152,378 - 152,378  Asset backed securities - 24,467 - 24,467  U.S. government bonds - 17,068 - 17,068  Commercial paper - 9,840 - 9,840  Certificates of deposit - 8,600 - 8,600  Agency bonds - 2,401 - 2,401  International government bonds - 1,456 - 1,456  Municipal bonds - 1,407 - 1,407  Total marketable securities - 217,617 - 217,617   Equity mutual funds (2) 2,207 - - 2,207  Foreign currency exchange contracts (3) - 2,556 - 2,556  Liabilities  Foreign currency exchange contracts (3) - 4,160 - 4,160  Deferred compensation (4) 2,207 - - 2,207  Interest rate swaps (5) - 209 - 209     Quoted Prices Significant  in Active Other Significant  Markets for Observable Unobservable  Identical Assets Inputs Inputs Balance at  As of December 31, 2015 (Level 1) (Level 2) (Level 3) December 31, 2015   Assets  Money market funds (1) $ 15,490 $ - $ - $ 15,490  Agency bonds - 1,999 - 1,999  Commercial paper - 1,800 - 1,800   Marketable Securities  Corporate bonds - 177,613 - 177,613  U.S. government bonds - 12,871 - 12,871  Agency bonds - 12,065 - 12,065  Certificates of deposit - 3,500 - 3,500  Commercial paper - 3,491 - 3,491  International government bonds - 1,459 - 1,459  Municipal bonds - 1,399 - 1,399  Treasury bills - 1,193 - 1,193  Total marketable securities - 213,591 - 213,591   Equity mutual funds (2) 2,264 - - 2,264  Foreign currency exchange contracts (3) - 4,876 - 4,876  Liabilities  Foreign currency exchange contracts (3) - 1,365 - 1,365  Deferred compensation (4) 2,264 - - 2,264  Interest rate swaps (5) - 384 - 384 _____________ (1) Money market funds, agency bonds and commercial paper with an original maturity of less than ninety days are included within cash and cash equivalents. The remaining balance of cash and cash equivalents as of Marc h 31, 2016 and December 31, 2015 consisted of demand deposits. Commercial paper and agency bonds with an original maturity of over ninety days are included within marketable securities. (2) Equity mutual funds relate to a deferred compensation plan that was assumed as part of a previous business combination. This amount is included within other lon g-term assets . See number (4) below for a discussion of the related deferred compensation liability. (3) Foreign currency exchange contracts are included within other current assets ; other long-term assets ; accrued liabilities; or other long-term liabilities depending on the gain (loss) position and anticipated settlement date. (4) A deferred compensation plan assumed as part of a previous business combination is included within accrued liabilities and other long-term liabilities. The fair value of our deferred compensation plan is indexed to the performance of the underlying equity mutual funds discussed in number (2) above. (5) Interest rate swaps are included within accrued liabilities.  The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts receivable and accounts payable, approximate carrying value due to their short maturity.

Hedging Instruments

Hedging Instruments	3 Months Ended
	Mar. 31, 2016
Hedging Instruments [Abstract]
Hedging Instruments	Note 1 6 . HEDGING Instruments Disclosure within this note is presented to provide transparency about how and why we use derivative and non-derivative instruments (collectively “hedging instruments”) , how the instruments and related hedged items are accounted for, and how the instruments and related hedged items affect our financial position, results of operations and cash flows. We are exposed to certain risks related to our ongoing business operations. The primary risks that we manage by using hedging instruments are foreign currency exchange risk and interest rate risk. Our subsidiaries enter into foreign currency exchange contracts to manage the exchange risk associated with their forecasted intercompany inventory purchases and sales for the next year. From time to time, we may also enter into other foreign currency exchange contracts or foreign-denominated debt issuances to minimize the impact of foreign currency fluctuations associated with specific balance sheet exposures , including net investments in certain foreign subsidiaries . We enter into interest rate swaps to minimize the impact of interest rate fluctuations associated with borrowings under our variable-rate Credit Facility. The primary purpose of our foreign currency hedging activities is to protect against the volatility associated with foreign currency transactions, including transactions denominated in euro, British pound, Japanese yen, Canadian dollar, Australian dollar and Swiss franc. We also utilize natural hedges to mitigate our transaction and commitment exposures. Our corporate policy prescribes the range of allowable hedging activity. We enter into foreign curre ncy exchange contracts with well-capitalized multinational financial institutions, and we do not hold or engage in t ransactions involving hedging instruments for purposes other than risk management. Our accounting policies for these contracts are based on the designation of such instruments as hedging transactions.  We recognize all hedging instruments on the balance sheet at fair value at the balance sheet date. I nstruments that do not qualify for hedge accounting treatment must be recorded at fair value through earnings. To qualify for hedge accounting treatment, cash flow and net investment hedges must be highly effective in offsetting changes to expected future cas h flows or fair value on hedged transactions. If the instrument qualifies for hedge accounting, c hanges in the fair value of the hedging instrument from the effective portion of the hedge are deferred in AOCI, net of tax, and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. We immediately record in earn ings the extent to which a hedging instrument is not effective in achieving offsetting changes in fair value. We de-designate hedging instruments from hedge accounting when the likelihood of the hedged transaction occurring becomes less than probable. For de-designated instruments, the gain or loss from the time of de-designation through maturity of the instrument is recognized in earnings. Any gain or loss in AOCI at the time of de-designation is reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. See Note 1 1 to the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q for further information regarding the effect of hedging instruments on the condensed consolidated statements of operations for the three months ended March 31, 2016 and 201 5 .  We enter into master netting arrangements with the counterparties to our derivative transactions which permit certain outstanding receivables and payables to be offset in the event of default. Our derivative contracts do not require either party to post cash collateral. We elect to present our derivative assets and liabilities in the accompanying condensed consolidated balance sheets on a gross basis. All cash flows related to our foreign currency exchange contracts and interest rate swaps are classified as operating cash flows, which is consistent with the cash flow treatment of the underlying items being hedged. Cash Flow Hedges We have designated our foreign currency exchange contracts and variable-to-fixed interest rate swaps as cash flow hedges as these derivative instruments mitigate the exposure to variability in the cash flows of forecasted transactions attributable to foreign currency exchange and interest rates. Unless noted otherwise, we have also designated our derivative instruments as qualifying for hedge accounting treatment. We did not de-designate any instruments from hedge accounting treatment during the three months ended March 31, 2016 or 201 5 . Gains or losses related to hedge ineffectiveness recognized in earnings during the three months ended March 31, 2016 and 201 5 were not material . At March 31, 2016 , the estimated amount of net losses, net of income tax benefit , which are expected to be reclassified out of AOCI and into earnings within the next 12 months, is $1.0 m illion if exchange and interest rates do not fluctuate from the levels at March 31, 2016 . We hedge approximately 85% of the estimated exposure from intercompany product purchases and sales denominated in the euro, British pound, Canadian dollar, Japanese yen, Australian dollar and Swiss franc. We have additional unhedged foreign currency exposures related to foreign services and emerging markets where it is not practical to hedge. We primarily utilize foreign currency exchange contracts with durations of less than 24 months. Quarterly, we enter into contracts to hedge incremental portions of anticipated foreign currency transactions for the current and following year. As a result, our risk with respect to foreign currency exchange rate fluctuations and the notional value of foreign currency exchange contracts may vary throughout the year. The U.S. dollar is the currency purchased or sold in all of our foreign currency exchange contracts. The notional amount of foreign currency exchange contracts to hedge forecasted intercompany inventory purchases and sales totaled $204.3 million and $176.1 million at March 31, 2016 and December 31, 2015 , respectively. We have entered into forward fixed interest rate swap agreements to manage the economic effect of variable interest obligations on amounts borrowed under the terms of our Credit Facility. Beginning on March 30, 2012, the variable interest rate associated with $40 million of borrowings outstanding under the Credit Facility became effectively fixed at 1.36% plus the ra nge of applicable interest rate fixed credit spreads (“Credit Spread”) through June 30, 2016. Beginning on March 28, 2013, the variable interest rate associated with an additional $40 million of borrowings outstanding under the Credit Facility became effectively fixed at 1.64% plus the Credit Spread through June 30, 2016.  Net Investment Hedge  In June 2015, we issued and sold through a private placement an aggregate principal amount of €88.9 million (approximately $100 million) in euro-denominated 1.785% Series C Senior Notes due June 18, 2025. We have designated these euro-denominated notes as a hedge of our euro net investment in certain foreign subsidiaries to reduce the volatility in stockholders’ equity caused by changes in foreign currency exchange rates in the euro relative to the U.S. dollar. As a result of this designation, gains and losses from the change in translated U.S. dollar value of these euro-denominated notes are recorded in AOCI rather than to earnings. We recorded a $2.2 million gain , net of income tax, within AOCI as a result of this net investment hedge for the three months ended March 31, 2016 . This unrealized gain recorded at March 31, 2016 will not be reclassified in earnings until the complete or substantially complete liquidation of the net investment in the hedged foreign operations or all or a portion of the hedge no longer qualifies for hedge accounting treatment. See Note 11 to the consolidated financial statements included in our 2015 Annual Report for further information regarding the issuance of these euro-denominated notes.  Fair Values of Hedging Instruments Designated as Hedges in Consolidated Balance Sheets  The fair values of hedging instruments and their respective classification on the condensed consolidated balance sheets and amounts subject to offset under master netting arrangements consisted of the following (in thousands) :   Hedging Assets  March 31, December 31,  2016 2015   Derivatives designated as hedging instruments Balance Sheet Classification  Foreign currency exchange contracts Other current assets $ 2,482 $ 4,876  Foreign currency exchange contracts Other long-term assets 74 -  Total derivative instruments presented as cash flow hedges on the balance sheet 2,556 4,876  Gross amounts subject to master netting arrangements not offset on the balance sheet 1,809 1,268  Net amount $ 747 $ 3,608     Hedging Liabilities  March 31, December 31,  2016 2015   Derivatives designated as hedging instruments Balance Sheet Classification  Foreign currency exchange contracts Accrued liabilities $ 3,342 $ 1,365  Foreign currency exchange contracts Other long-term liabilities 818 -  Interest rate swaps Accrued liabilities 209 384  Total derivative instruments presented as cash flow hedges on the balance sheet 4,369 1,749  Foreign currency borrowings designated as net investment hedge on the balance sheet Long-term debt 100,622 97,085  Total hedging instruments presented on the balance sheet 104,991 98,834  Gross amounts subject to master netting arrangements not offset on the balance sheet 1,809 1,268  Net amount $ 103,182 $ 97,566  The effect of derivative instruments designated as cash flow hedges on the condensed consolidated balance sheets consisted of the following (in thousands) :   Gain (Loss) Recognized in AOCI on Derivative Instruments (Effective Portion)  For the Three Months Ended  March 31,  Derivative instruments 2016 2015   Cash flow hedging derivatives:  Foreign currency exchange contracts, net of tax $ (3,806) $ 4,179  Interest rate swaps, net of tax 111 42  Total cash flow hedges $ (3,695) $ 4,221 

Accounting Policies (Policy)

Accounting Policies (Policy)	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
New Accounting Pronouncements Adopted	New Accounting Pronouncements Adopted  Deferred Income Taxes  During the first quarter of 2016, the C ompany early adopted Financial Accounting Standards Board (“ FASB ”) amendments which require us to classify all deferred tax assets and liabilities as noncurrent within our condensed consolidated balance sheet. In accordance with the FASB’s permitted transition guidance, we applied this guidance prospectively and did not revise our prior period balance sheet presentation for the effects of this amendment. These amendments did not have a material impact on our financial statements.  Deferred Financing Costs  Effective January 1, 2016, the C ompany adopted FASB amendments that require debt issuance costs related to a recognized debt liability be presented within the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. This reclassification of the presentation of deferred financing costs did not have a material impact on other long-term assets or long-term debt amounts reported in our March 31, 2016 condensed consolidated balance sheet and additionall y would not have a material impact on such amounts reported in a prior period. As such, these amendments have been reflected prospectively in 2016; prior period amounts have not been revised for the effects of this amendment.  The FASB confirmed in August 2015 that the aforementioned amendments did not address the presentation or subsequent measurement of debt issuance costs related to line-of-credit arrangements. For line-of-credit arrangements, borrowers have the option of presenting debt issuance costs as an asset which is subsequently amortized ratably over the term of the line-of-credit arrangement, regardless of whether there are any related outstanding borrowings. As such, we continue to present deferred financing costs associated with our unsecured revolving credit facility within other long-term assets in the accompanying condensed consolidated balance sheets. Following recognition within the condensed consolidated balance sheets, all deferred financing costs are amortized to interest expense using the effective interest rate method over the term of the related debt agreement. These amendments did not have a material impact on our financial statements.  Additional Pronou n cements  During the three months ended March 31, 2016, the adoption of other effective FASB amendments addressing measurement-period adjustments for business combinations, accounting for cloud computing arrangements that include a software license, and to the fair value hierarchy of investments measured at net asset value did not have a material impact on our financial statements. 
New Accounting Pronouncements Not Yet Adopted	New Accounting Pronouncements Not Yet Adopted  In May 2014, the FASB issued an amendment which will replace most of the existing revenue recognition guidance within U.S. GAAP. The core principle of this guidance is that an entity should recognize revenue for the transfer of goods or services to customers in an amount that it expects to be entitled to receive for those goods or services. In doing so, companies will be required to make certain judgments and estimates, including identifying contract performance obligations, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price among separate performance obligations. Additionally, the amendment requires disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, significant judgments reached in the application of the guidance and assets recognized from the costs to obtain or fulfill a contract. In July 2015, the FASB voted to defer the effective date of the amendment to apply to public business entities for annual and interim periods ending after December 15, 2017. The amendment allows for two methods of adoption: a full retrospective method or a modified retrospective approach with the cumulative effect recognized at the date of initial application. We are in the process of determining the method of adoption and the impact of this amendment on our consolidated financial statements.  In August 2014, the FASB issued an amendment that requires management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. The amendments in this update provide guidance about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern for one year after the date that the financial statements are issued and to provide related footnote disclosures. In doing so, the amendments should reduce diversity in the timing and content of footnote disclosures. The amendments in this update apply to all entities and are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. This amendment is not expected to have a material impact on our financial statements.  In February 2015, the FASB issued amendments which change the analysis that a reporting entity must perform to determine whether it should consolidate certain types of legal entities, placing more emphasis on risk of loss when determining a controlling financial interest. The amendments in this update apply to all entities and are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. This amendment is not expected to have a material impact on our financial statements.  In July 2015, the FASB issued amendments which simplify the existing guidance which requires entities to subsequently measure inventory at the lower of cost or market value. Under the amendments, an entity should measure inventory valued using a first-in, first-out or average cost method at the lower of cost or net realizable value, which is defined as the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. This update is effective for public business entities during fiscal years beginning after December 15, 2016. Early adoption is permitted. This amendment is not expected to have a material impact on our financial statements.  In February 2016, the FAS B issued amendments to increase transparency and comparability among organizations’ leasing arrangements. The principal difference from previous guidance is that effective upon adoption, the lease assets and lease liabilities arising from operating leases will be recognized in the statement of financial position. For public business en tities, the amendments in this u pdate are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. In transition, we are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach, including the option to utilize a number of practical expedients. We are i n the process of determining the impact of this amendment on our consolidated financial statements.  In March 2016, the FAS B issued amendments which simplify several aspects of the accounting for share-based payment transactions, including income tax consequences, recognition of stock compensation award forfeitures, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The most significant change resulting from these amendments is recording all the tax effects related to share-based payments at settlement through the income statement. Under existing guidance, tax benefits in excess of compensation costs (“windfalls”) are recorded in equity. Similar ly , tax deficiencies below compensation costs (“shortfalls”) are recorded in equity to the extent of previous windfalls, while shortfalls in excess of this are recorded to the income statement. For public business entities, this update is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted for any entity in any interim or annual period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. An entity that elects early adoption must adopt all of the amendments in the same period. We are in the process of determining the method of adoption and the impact of this amendment on our consolidated financial statements.

Share-Based Compensation (Polic

Share-Based Compensation (Policy)	3 Months Ended
	Mar. 31, 2016
Share-Based Compensation [Abstract]
Share-Based Compensation Policy	We determine the assumptions used in the valuation of option awards as of the date of grant. Differences in the expected stock price volatility, expected term or risk-free interest rate may necessitate distinct valuation assumptions at each grant date. As such, we may use different assumptions for options granted throughout the year. Option awards are granted with an exercise price equal to the closing market price of our common stock at the date of grant. We have never paid any cash dividends on our common stock, and we have no intention to pay such a dividend at this time; therefore, we assume that no dividends will be paid over the expected terms of option awards.

Inventories (Policy)

Inventories (Policy)	3 Months Ended
	Mar. 31, 2016
Inventories [Abstract]
Inventories Policy	Inventories, which are stated at the lower of cost (first-in, first-out) or market, include material, conversion costs and inbound freight charges.

Earnings Per Share (Policy)

Earnings Per Share (Policy)	3 Months Ended
	Mar. 31, 2016
Earnings Per Share [Abstract]
Earnings Per Share Policy	Basic earnings per share is computed by dividing net income attributable to IDEXX Laboratories, Inc. stockholders by the weighted average number of shares of common stock and vested deferred stock units outstanding during the year. The computation of diluted earnings per share is similar to the computation of basic earnings per share, except that the denominator is increased for the assumed exercise of dilutive options and assumed issuance of unvested restricted stock units and unvested deferred stock units using the treasury stock method unless the effect is anti-dilutive. The treasury stock method assumes that proceeds, including cash received from the exercise of employee stock options, the total unrecognized compensation expense for unvested share-based compensation awards and the excess tax benefits resulting from share-based compensation tax deductions in excess of the related expense recognized for financial reporting purposes, would be used to purchase our common stock at the average market price during the period. Vested deferred stock units outstanding are included in shares outstanding for basic and diluted earnings per share because the associated shares of our common stock are issuable for no cash consideration, the number of shares of our common stock to be issued is fixed and issuance is not contingent.

Fair Value Measurements (Policy

Fair Value Measurements (Policy)	3 Months Ended
	Mar. 31, 2016
Fair Value Measurements [Abstract]
Fair Value Measurements Policy	U.S. GAAP defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. U.S. GAAP requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. The Company has certain financial assets and liabilities that are measured at fair value on a recurring basis, certain nonfinancial assets and liabilities that may be measured at fair value on a nonrecurring basis and certain financial assets and liabilities that are not measured at fair value in our condensed consolidated balance sheets but for which we disclose the fair value. The fair value disclosures of these assets and liabilities are based on a three-level hierarchy, which is defined as follows : Level 1 Quoted prices in active markets for identical assets or liabilities that the entity can access at the measurement date. Level 2 Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. We did not have any transfers between Level 1 and Level 2 or transfers in or out of Level 3 of the fair value hierarchy during the three months ended March 31, 2016.  Our marketable debt securities are initially valued at the transaction price and are subsequently remeasured to fair value as of the balance sheet date utilizing third- party pricing services. The pricing services utilize industry standard valuation models, i ncluding both income and market- based approaches and observable market inputs to determine value. Observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers and other industry and economic events. We validate t he prices provided by our third- party pricing services by obtaining independent market values from other pricing sources and analyzing pricing data in certain instances.  Our foreign currency exchange contracts and interest rate swap agreements are measured at fair value on a recurring basis in our accompanying condensed consolidated balance sheets. We measure the fair value of our foreign currency exchange contracts classified as derivative instruments using an income approach, based on prevailing market forward rates less the contract rate multiplied by the notional amount. The product of this calculation is then adjusted for counterparty risk. We measure the fair value of our interest rate swaps classified as derivative instruments using an income approach, utilizing a discounted cash flow analysis based on the terms of the contract and the interest rate curve adjusted for counterparty risk. The amount outstanding under our unsecured revolving credit facility (“Credit Facility”) and long-term debt are measured at carrying value in our accompanying condensed consolidated balance sheets though we disclose the fair value of these financial instruments. We determine the fair value of the amount outstanding under our Credit Facility and long-term debt using an income approach, utilizing a discounted cash flow analysis based on current market interest rates for debt issues with similar remaining years to maturity, adjusted for applicable credit risk. Our Credit Facility and l ong-term debt are valued using L evel 2 inputs.

Hedging Instuments (Policy)

Hedging Instuments (Policy)	3 Months Ended
	Mar. 31, 2016
Hedging Instruments [Abstract]
Derivatives Policy	We are exposed to certain risks related to our ongoing business operations. The primary risks that we manage by using hedging instruments are foreign currency exchange risk and interest rate risk. Our subsidiaries enter into foreign currency exchange contracts to manage the exchange risk associated with their forecasted intercompany inventory purchases and sales for the next year. From time to time, we may also enter into other foreign currency exchange contracts or foreign-denominated debt issuances to minimize the impact of foreign currency fluctuations associated with specific balance sheet exposures , including net investments in certain foreign subsidiaries . We enter into interest rate swaps to minimize the impact of interest rate fluctuations associated with borrowings under our variable-rate Credit Facility. The primary purpose of our foreign currency hedging activities is to protect against the volatility associated with foreign currency transactions, including transactions denominated in euro, British pound, Japanese yen, Canadian dollar, Australian dollar and Swiss franc. We also utilize natural hedges to mitigate our transaction and commitment exposures. Our corporate policy prescribes the range of allowable hedging activity. We enter into foreign curre ncy exchange contracts with well-capitalized multinational financial institutions, and we do not hold or engage in t ransactions involving hedging instruments for purposes other than risk management. Our accounting policies for these contracts are based on the designation of such instruments as hedging transactions.  We recognize all hedging instruments on the balance sheet at fair value at the balance sheet date. I nstruments that do not qualify for hedge accounting treatment must be recorded at fair value through earnings. To qualify for hedge accounting treatment, cash flow and net investment hedges must be highly effective in offsetting changes to expected future cas h flows or fair value on hedged transactions. If the instrument qualifies for hedge accounting, c hanges in the fair value of the hedging instrument from the effective portion of the hedge are deferred in AOCI, net of tax, and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. We immediately record in earn ings the extent to which a hedging instrument is not effective in achieving offsetting changes in fair value. We de-designate hedging instruments from hedge accounting when the likelihood of the hedged transaction occurring becomes less than probable. For de-designated instruments, the gain or loss from the time of de-designation through maturity of the instrument is recognized in earnings. Any gain or loss in AOCI at the time of de-designation is reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. See Note 1 1 to the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q for further information regarding the effect of hedging instruments on the condensed consolidated statements of operations for the three months ended March 31, 2016 and 201 5 .  We enter into master netting arrangements with the counterparties to our derivative transactions which permit certain outstanding receivables and payables to be offset in the event of default. Our derivative contracts do not require either party to post cash collateral. We elect to present our derivative assets and liabilities in the accompanying condensed consolidated balance sheets on a gross basis. All cash flows related to our foreign currency exchange contracts and interest rate swaps are classified as operating cash flows, which is consistent with the cash flow treatment of the underlying items being hedged. Cash Flow Hedges We have designated our foreign currency exchange contracts and variable-to-fixed interest rate swaps as cash flow hedges as these derivative instruments mitigate the exposure to variability in the cash flows of forecasted transactions attributable to foreign currency exchange and interest rates. Unless noted otherwise, we have also designated our derivative instruments as qualifying for hedge accounting treatment.

Share-Based Compensation (Table

Share-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2016
Share-Based Compensation [Abstract]
Schedule Of Weighted Averages Of The Assumptions Used In Estimating The Fair Value Of Stock Option Awards	  For the Three Months Ended  March 31,  2016 2015   Expected stock price volatility 25 % 23 %  Expected term, in years 5.7 5.6  Risk-free interest rate 1.2 % 1.5 %   Weighted average fair value of options granted $ 17.54 $ 19.99 

Marketable Securities (Tables)

Marketable Securities (Tables)	3 Months Ended
	Mar. 31, 2016
Marketable Securities [Abstract]
Amortized Cost And Fair Value Of Marketable Securities	  As of March 31, 2016 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value   Corporate bonds $ 152,383 $ 85 $ (90) $ 152,378  Asset backed securities 24,430 37 - 24,467  U.S. government bonds 17,057 11 - 17,068  Commercial paper 9,840 - - 9,840  Certificates of deposit 8,600 - - 8,600  Agency bonds 2,401 - - 2,401  International government bonds 1,457 - (1) 1,456  Municipal bonds 1,400 7 - 1,407  Total marketable securities $ 217,568 $ 140 $ (91) $ 217,617   As of December 31, 2015 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value   Corporate bonds $ 177,810 $ 24 $ (221) $ 177,613  U.S. government bonds 12,881 - (10) 12,871  Agency bonds 12,068 - (3) 12,065  Certificates of deposit 3,500 - - 3,500  Commercial paper 3,491 - - 3,491  International government bonds 1,462 - (3) 1,459  Municipal bonds 1,400 - (1) 1,399  Treasury bill 1,192 1 - 1,193  Total marketable securities $ 213,804 $ 25 $ (238) $ 213,591 
Contractual Maturities Of Marketable Securities	  As of March 31, 2016 Amortized Cost Fair Value   Due in one year or less $ 162,177 $ 162,198  Due after one year through three years 55,391 55,419  $ 217,568 $ 217,617 

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2016
Inventories [Abstract]
Schedule Of Components Of Inventories	  March 31, December 31,  2016 2015   Raw materials $ 32,029 $ 31,184  Work-in-process 19,439 18,698  Finished goods 132,291 138,951  Inventories $ 183,759 $ 188,833 

Other Current and Long-Term A33

Other Current and Long-Term Assets (Tables)	3 Months Ended
	Mar. 31, 2016
Other Current and Long-Term Assets [Abstract]
Schedule Of Other Current Assets	  March 31, December 31,  2016 2015   Prepaid expenses $ 23,970 $ 27,244  Taxes receivable 13,219 11,792  Customer acquisition costs, net 16,573 16,412  Other assets 8,843 6,621  Other current assets $ 62,605 $ 62,069 
Schedule Of Other Noncurrent Assets	  March 31, December 31,  2016 2015   Investment in long-term product supply arrangements $ 12,305 $ 12,165  Customer acquisition costs, net 45,663 43,570  Other assets 33,465 29,755  Other long-term assets $ 91,433 $ 85,490 

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2016
Accrued Liabilities [Abstract]
Schedule Of Accrued Liabilities	  March 31, December 31,  2016 2015   Accrued expenses $ 62,649 $ 65,665  Accrued employee compensation and related expenses 46,688 77,027  Accrued taxes 24,815 18,963  Accrued customer programs 44,115 43,875  Accrued liabilities $ 178,267 $ 205,530 

Repurchases Of Common Stock (Ta

Repurchases Of Common Stock (Tables)	3 Months Ended
	Mar. 31, 2016
Repurchases Of Common Stock [Abstract]
Schedule Of Common Stock Repurchases	  March 31, March 31,  2016 2015   Shares repurchased (1) 708 1,718  Shares acquired through employee surrender (1) 52 61  Total shares repurchased (1) 760 1,779   Cost of shares repurchased $ 49,715 $ 133,647  Cost of employee surrenders 3,529 4,866  Total cost of shares repurchased $ 53,244 $ 138,513   Average cost per share $ 70.06 $ 77.85 _____________ (1) Shares repurchased and acquired through employee surrender for payment of minimum required withholding taxes on and before June 15, 2015 and the associated average cost per share have been adjusted to reflect the June 15, 2015 two -for-one stock split. Actual shares repurchased were approximately 890,000 for the three months ended March 31, 2015 .

Accumulated Other Comprehensi36

Accumulated Other Comprehensive Income (Tables)	3 Months Ended
	Mar. 31, 2016
Accumulated Other Comprehensive Income [Abstract]
Schedule Of Accumulated Other Comprehensive Income	  For the Three Months Ended March 31, 2016 Unrealized Gain (Loss) on Investments, Net of Tax Unrealized Gain (Loss) on Derivative Instruments, Net of Tax Unrealized Gain on Net Investment Hedge, Net of Tax Cumulative Translation Adjustment Total   Balance as of December 31, 2015 $ (225) $ 2,217 $ 1,894 $ (46,151) $ (42,265)  Other comprehensive (loss) income before reclassifications 205 (3,266) 2,224 6,016 5,179  Gains reclassified from accumulated other comprehensive income - (429) - - (429)  Balance as of March 31, 2016 $ (20) $ (1,478) $ 4,118 $ (40,135) $ (37,515) 
Summary Of Reclassifications Out Of Accumulated Other Comprehensive Income	  Details about AOCI Components Affected Line Item in the Statement of Operations Amounts Reclassified from AOCI For the Three Months Ended March 31,  2016 2015  Gains (losses) on derivative instruments classified as cash flow hedges included in net income:  Foreign currency exchange contracts Cost of revenue $ 809 $ 4,479  Interest rate swaps Interest expense (210) (262)  Total gains before tax 599 4,217  Tax expense 170 1,253  Gains, net of tax $ 429 $ 2,964  

Earnings Per Share (Tables)

Earnings Per Share (Tables)	3 Months Ended
	Mar. 31, 2016
Earnings Per Share [Abstract]
Schedule Of Reconciliation Of Shares Outstanding For Basic And Diluted Earnings Per Share	  For the Three Months Ended  March 31,  2016 2015   Shares outstanding for basic earnings per share 89,924 94,280   Shares outstanding for diluted earnings per share:  Shares outstanding for basic earnings per share 89,924 94,280  Dilutive effect of share-based payment awards 914 1,241  90,838 95,521 
Schedule Of Number Of Anti-Dilutive Stock Options	  For the Three Months Ended  March 31,  2016 2015   Weighted average number of shares underlying anti-dilutive options 1,044 363   Weighted average number of shares underlying anti-dilutive restricted stock units - 67 

Segment Reporting (Tables)

Segment Reporting (Tables)	3 Months Ended
	Mar. 31, 2016
Segment Reporting [Abstract]
Summary Of Segment Performance	   For the Three Months Ended March 31,  CAG Water LPD Other Unallocated Amounts Consolidated Total  2016  Revenue $ 357,639 $ 23,552 $ 30,856 $ 5,503 $ - $ 417,550   Income (loss) from operations $ 61,378 $ 9,679 $ 4,570 $ (837) $ (997) $ 73,793  Interest expense, net (7,484)  Income before provision for income taxes 66,309  Provision for income taxes 20,284  Net income 46,025  Less: Net income attributable to noncontrolling interest 6  Net income attributable to IDEXX Laboratories, Inc. stockholders $ 46,019   2015  Revenue $ 324,531 $ 21,698 $ 31,270 $ 4,978 $ - $ 382,477   Income (loss) from operations $ 53,518 $ 9,361 $ 6,956 $ (322) $ 3,290 $ 72,803  Interest expense, net (5,879)  Income before provision for income taxes 66,924  Provision for income taxes 20,346  Net income 46,578  Less: Net loss attributable to noncontrolling interest (16)  Net income attributable to IDEXX Laboratories, Inc. stockholders $ 46,594   
Summary Of Revenue By Product And Service Category	  For the Three Months Ended  March 31,  2016 2015  CAG segment revenue:  CAG Diagnostics recurring revenue: $ 305,510 $ 278,766  IDEXX VetLab ® consumables 107,959 98,392  IDEXX VetLab service and accessories 13,757 13,530  Rapid assay products 43,086 43,637  Reference laboratory diagnostic and consulting services 140,708 123,207  CAG Diagnostics capital - instruments 22,974 20,113  Customer information management and diagnostic imaging systems 29,155 25,652  CAG segment revenue 357,639 324,531   Water segment revenue 23,552 21,698  LPD segment revenue 30,856 31,270  Other segment revenue 5,503 4,978  Total revenue $ 417,550 $ 382,477 

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2016
Fair Value Measurements [Abstract]
Schedule Of Fair Value Of Assets And Liabilities Measured On Recurring Basis	  Quoted Prices Significant  in Active Other Significant  Markets for Observable Unobservable  Identical Assets Inputs Inputs Balance at  As of March 31, 2016 (Level 1) (Level 2) (Level 3) March 31, 2016   Assets  Money market funds (1) $ 9,213 $ - $ - $ 9,213  Commercial paper (1) - 2,299 - 2,299   Marketable Securities  Corporate bonds - 152,378 - 152,378  Asset backed securities - 24,467 - 24,467  U.S. government bonds - 17,068 - 17,068  Commercial paper - 9,840 - 9,840  Certificates of deposit - 8,600 - 8,600  Agency bonds - 2,401 - 2,401  International government bonds - 1,456 - 1,456  Municipal bonds - 1,407 - 1,407  Total marketable securities - 217,617 - 217,617   Equity mutual funds (2) 2,207 - - 2,207  Foreign currency exchange contracts (3) - 2,556 - 2,556  Liabilities  Foreign currency exchange contracts (3) - 4,160 - 4,160  Deferred compensation (4) 2,207 - - 2,207  Interest rate swaps (5) - 209 - 209     Quoted Prices Significant  in Active Other Significant  Markets for Observable Unobservable  Identical Assets Inputs Inputs Balance at  As of December 31, 2015 (Level 1) (Level 2) (Level 3) December 31, 2015   Assets  Money market funds (1) $ 15,490 $ - $ - $ 15,490  Agency bonds - 1,999 - 1,999  Commercial paper - 1,800 - 1,800   Marketable Securities  Corporate bonds - 177,613 - 177,613  U.S. government bonds - 12,871 - 12,871  Agency bonds - 12,065 - 12,065  Certificates of deposit - 3,500 - 3,500  Commercial paper - 3,491 - 3,491  International government bonds - 1,459 - 1,459  Municipal bonds - 1,399 - 1,399  Treasury bills - 1,193 - 1,193  Total marketable securities - 213,591 - 213,591   Equity mutual funds (2) 2,264 - - 2,264  Foreign currency exchange contracts (3) - 4,876 - 4,876  Liabilities  Foreign currency exchange contracts (3) - 1,365 - 1,365  Deferred compensation (4) 2,264 - - 2,264  Interest rate swaps (5) - 384 - 384 _____________ (1) Money market funds, agency bonds and commercial paper with an original maturity of less than ninety days are included within cash and cash equivalents. The remaining balance of cash and cash equivalents as of Marc h 31, 2016 and December 31, 2015 consisted of demand deposits. Commercial paper and agency bonds with an original maturity of over ninety days are included within marketable securities. (2) Equity mutual funds relate to a deferred compensation plan that was assumed as part of a previous business combination. This amount is included within other lon g-term assets . See number (4) below for a discussion of the related deferred compensation liability. (3) Foreign currency exchange contracts are included within other current assets ; other long-term assets ; accrued liabilities; or other long-term liabilities depending on the gain (loss) position and anticipated settlement date. (4) A deferred compensation plan assumed as part of a previous business combination is included within accrued liabilities and other long-term liabilities. The fair value of our deferred compensation plan is indexed to the performance of the underlying equity mutual funds discussed in number (2) above. (5) Interest rate swaps are included within accrued liabilities.

Hedging Instruments (Tables)

Hedging Instruments (Tables)	3 Months Ended
	Mar. 31, 2016
Derivative [Line Items]
Gain/(Loss) Recognized In Other Comprehensive Income On Derivative Instruments (Effective Portion)	  Gain (Loss) Recognized in AOCI on Derivative Instruments (Effective Portion)  For the Three Months Ended  March 31,  Derivative instruments 2016 2015   Cash flow hedging derivatives:  Foreign currency exchange contracts, net of tax $ (3,806) $ 4,179  Interest rate swaps, net of tax 111 42  Total cash flow hedges $ (3,695) $ 4,221 
Assets [Member]
Derivative [Line Items]
Schedule Of Fair Values And Balance Sheet Classifications Of Derivatives Designated As Hedging Instruments	  Hedging Assets  March 31, December 31,  2016 2015   Derivatives designated as hedging instruments Balance Sheet Classification  Foreign currency exchange contracts Other current assets $ 2,482 $ 4,876  Foreign currency exchange contracts Other long-term assets 74 -  Total derivative instruments presented as cash flow hedges on the balance sheet 2,556 4,876  Gross amounts subject to master netting arrangements not offset on the balance sheet 1,809 1,268  Net amount $ 747 $ 3,608 
Liabilities [Member]
Derivative [Line Items]
Schedule Of Fair Values And Balance Sheet Classifications Of Derivatives Designated As Hedging Instruments	  Hedging Liabilities  March 31, December 31,  2016 2015   Derivatives designated as hedging instruments Balance Sheet Classification  Foreign currency exchange contracts Accrued liabilities $ 3,342 $ 1,365  Foreign currency exchange contracts Other long-term liabilities 818 -  Interest rate swaps Accrued liabilities 209 384  Total derivative instruments presented as cash flow hedges on the balance sheet 4,369 1,749  Foreign currency borrowings designated as net investment hedge on the balance sheet Long-term debt 100,622 97,085  Total hedging instruments presented on the balance sheet 104,991 98,834  Gross amounts subject to master netting arrangements not offset on the balance sheet 1,809 1,268  Net amount $ 103,182 $ 97,566 

Basis Of Presentation And Pri41

Basis Of Presentation And Principles Of Consolidation (Details)	3 Months Ended
	Mar. 31, 2016
Basis Of Presentation And Principles Of Consolidation [Abstract]
Stock split	2

Share-Based Compensation (Narra

Share-Based Compensation (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Share-Based Compensation [Abstract]
Fair value of share-based compensation awards, granted	$ 24	$ 22
Unrecognized compensation expense, net of estimated forfeitures, for unvested share-based compensation awards outstanding	$ 54.7
Weighted average recognition period for unrecognized compensation expense, in years	2 years 3 months 18 days

Share-Based Compensation (Sched

Share-Based Compensation (Schedule Of Weighted Averages Of The Assumptions Used In Estimating The Fair Value Of Stock Option Awards) (Details) - $ / shares	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Share-Based Compensation [Abstract]
Expected stock price volatility	25.00%	23.00%
Expected term, in years	5 years 8 months 12 days	5 years 7 months 6 days
Risk-free interest rate	1.20%	1.50%
Weighted average fair value of options granted	$ 17.54	$ 19.99

Marketable Securities (Amortize

Marketable Securities (Amortized Cost And Fair Value Of Marketable Securities) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 217,568	$ 213,804
Gross Unrealized Gains	140	25
Gross Unrealized Losses	(91)	(238)
Fair Value	217,617	213,591
Marketable securities that we consider to be other-than-temporarily impaired	0
Corporate Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	152,383	177,810
Gross Unrealized Gains	85	24
Gross Unrealized Losses	(90)	(221)
Fair Value	152,378	177,613
Asset-backed Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	24,430
Gross Unrealized Gains	37
Fair Value	24,467
U.S. Government Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	17,057	12,881
Gross Unrealized Gains	11
Gross Unrealized Losses		(10)
Fair Value	17,068	12,871
Commercial Paper - Marketable Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	9,840	3,491
Fair Value	9,840	3,491
Certificates Of Deposit [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	8,600	3,500
Fair Value	8,600	3,500
Agency Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	2,401	12,068
Gross Unrealized Losses		(3)
Fair Value	2,401	12,065
International Government Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	1,457	1,462
Gross Unrealized Losses	(1)	(3)
Fair Value	1,456	1,459
Municipal Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	1,400	1,400
Gross Unrealized Gains	7
Gross Unrealized Losses		(1)
Fair Value	$ 1,407	1,399
Treasury Bills [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		1,192
Gross Unrealized Gains		1
Fair Value		$ 1,193

Marketable Securities (Contract

Marketable Securities (Contractual Maturities Of Marketable Securities) (Details) $ in Thousands	Mar. 31, 2016USD ($)
Marketable Securities [Abstract]
Due in one year or less, Amortized Cost	$ 162,177
Due after one year through three years, Amortized Cost	55,391
Total marketable securities, Amortized Cost	217,568
Due in one year or less, Fair Value	162,198
Due after one year through three years, Fair Value	55,419
Total marketable securities, Fair Value	$ 217,617

Inventories (Schedule Of Compon

Inventories (Schedule Of Components Of Inventories) (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Inventories [Abstract]
Raw materials	$ 32,029	$ 31,184
Work-in-process	19,439	18,698
Finished goods	132,291	138,951
Inventories	$ 183,759	$ 188,833

Goodwil And Intangible Assets,

Goodwil And Intangible Assets, Net (Narrative) (Details) $ in Millions	3 Months Ended
	Mar. 31, 2016USD ($)
Goodwill and Intangible Assets, Net [Abstract]
Impairment charge	$ 1.1

Other Current and Long-Term A48

Other Current and Long-Term Assets (Schedule Of Other Current Assets) (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Other Current and Long-Term Assets [Abstract]
Prepaid expenses	$ 23,970	$ 27,244
Taxes receivable	13,219	11,792
Customer acquisition costs, net	16,573	16,412
Other assets	8,843	6,621
Other current assets	$ 62,605	$ 62,069

Other Current and Long-Term A49

Other Current and Long-Term Assets (Schedule Of Other Noncurrent Assets) (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Other Current and Long-Term Assets [Abstract]
Investment in long-term product supply arrangements	$ 12,305	$ 12,165
Customer acquisition costs, net	45,663	43,570
Other assets	33,465	29,755
Other long-term assets	$ 91,433	$ 85,490

Accrued Liabilities (Schedule O

Accrued Liabilities (Schedule Of Accrued Liabilities) (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Accrued Liabilities [Abstract]
Accrued expenses	$ 62,649	$ 65,665
Accrued employee compensation and related expenses	46,688	77,027
Accrued taxes	24,815	18,963
Accrued customer programs	44,115	43,875
Accrued liabilities	$ 178,267	$ 205,530

Repurchases Of Common Stock (De

Repurchases Of Common Stock (Details) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2016USD ($)$ / sharesshares	Mar. 31, 2015USD ($)$ / sharesshares
Share repurchases during the period	708,000	1,718,000
Shares acquired through employee surrender	52,000	61,000
Total shares repurchased	760,000	1,779,000
Cost of share repurchases during the period | $	$ 49,715	$ 133,647
Cost of employee surrenders | $	3,529	4,866
Total cost of shares repurchased | $	$ 53,244	$ 138,513
Average cost per share | $ / shares	$ 70.06	$ 77.85
Stock split	2
Treasury Stock [Member]
Total shares repurchased	890,000

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Income Taxes [Abstract]
Effective Tax Rate	30.60%	30.40%

Accumulated Other Comprehensi53

Accumulated Other Comprehensive Income (Schedule Of Accumulated Other Comprehensive Income) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016
Accumulated Other Comprehensive Income [Abstract]
Beginning balance, Unrealized Gain (Loss) on Investments, Net of Tax	$ (225)
Beginning balance, Unrealized Gain (Loss) on Derivative Instruments, Net of Tax	2,217
Beginning balance, Unrealized Gain On Net Investment Hedge, Net Of Tax	1,894
Beginning balance, Cumulative Translation Adjustment	(46,151)
Other comprehensive income (loss) before reclassifications, Unrealized Gain (Loss) on Investments, Net of Tax	205	$ 33
Other comprehensive income (loss) before reclassifications, Unrealized Gain (Loss) on Derivative Instruments, Net of Tax	(3,266)	7,185
Other comprehensive income (loss) before reclassifications, Unrealized Gain On Net Investment Hedge, Net Of Tax	2,224
Other comprehensive income (loss) before reclassifications, Cumulative Translation Adjustment	6,016	(20,232)
Other comprehensive income (loss) before reclassifications, Cumulative Translation Adjustment	(46,151)		$ (40,135)
Gains reclassified from accumulated other comprehensive income, Unrealized Gain (Loss) on Derivative Instruments, Net of Tax	(429)	$ (2,964)
Ending balance, Unrealized Gain (Loss) on Investments, Net of Tax	(20)
Ending balance, Unrealized Gain (Loss) on Derivative Instruments, Net of Tax	(1,478)
Ending balance, Unrealized Gain On Net Investment Hedge, Net Of Tax	4,118
Ending balance, Cumulative Translation Adjustment	(40,135)
Accumulated Other Comprehensive Income (Loss), Net of Tax, Beginning Balance	(42,265)
Accumulated Other Comprehensive Income, before Tax			$ 5,179
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	(429)
Accumulated Other Comprehensive Income (Loss), Net of Tax, Ending Balance	$ (37,515)

Accumulated Other Comprehensi54

Accumulated Other Comprehensive Income (Schedule of Reclassifications out of Accumulated Other Comprehensive Income) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Provision for income taxes	$ 20,284	$ 20,346
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	429
Reclassification out of Accumulated Other Comprehensive Income [Member]
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	599	4,217
Provision for income taxes	170	1,253
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	429	2,964
Foreign Currency Exchange Contracts [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	809	4,479
Interest Rate Swaps [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	$ (210)	$ (262)

Earnings Per Share (Schedule Of

Earnings Per Share (Schedule Of Reconciliation Of Shares Outstanding For Basic And Diluted Earnings Per Share) (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Earnings Per Share [Abstract]
Shares outstanding for basic earnings per share	89,924	94,280
Dilutive effect of share-based payment awards	914	1,241
Shares outstanding for diluted earnings per share	90,838	95,521

Earnings Per Share (Schedule 56

Earnings Per Share (Schedule Of Number Of Anti-Dilutive Stock Options) (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Stock Options [Member]
Antidilutive Securities [Line Items]
Weighted average number of shares underlying anti-dilutive options	1,044	363
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities [Line Items]
Weighted average number of shares underlying anti-dilutive options		67

Segment Reporting (Summary Of S

Segment Reporting (Summary Of Segment Performance) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Segment Reporting Information [Line Items]
Revenue	$ 417,550	$ 382,477
Income (loss) from operations	73,793	72,803
Interest expense, net	(7,484)	(5,879)
Income before provision for income taxes	66,309	66,924
Provision for income taxes	20,284	20,346
Net income	46,025	46,578
Less: Net income (loss) attributable to noncontrolling interest	6	(16)
Net income attributable to IDEXX Laboratories, Inc. stockholders	46,019	46,594
Depreciation and amortization	18,546	16,154
Expenditures for long-lived assets	21,906	23,017
CAG Segment [Member]
Segment Reporting Information [Line Items]
Revenue	357,639	324,531
Income (loss) from operations	61,378	53,518
Water Segment [Member]
Segment Reporting Information [Line Items]
Revenue	23,552	21,698
Income (loss) from operations	9,679	9,361
LPD Segment [Member]
Segment Reporting Information [Line Items]
Revenue	30,856	31,270
Income (loss) from operations	4,570	6,956
Other Segment [Member]
Segment Reporting Information [Line Items]
Revenue	5,503	4,978
Income (loss) from operations	(837)	(322)
Unallocated Amounts [Member]
Segment Reporting Information [Line Items]
Income (loss) from operations	$ (997)	$ 3,290

Segment Reporting (Summary Of R

Segment Reporting (Summary Of Revenue By Product And Service Category) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Segment Reporting Information [Line Items]
Revenue	$ 417,550	$ 382,477
CAG Diagnostics Recurring Revenue [Member]
Segment Reporting Information [Line Items]
Revenue	305,510	278,766
IDEXX Vetlab Consumables [Member]
Segment Reporting Information [Line Items]
Revenue	107,959	98,392
IDEXX VetLab Service and Accessories [Member]
Segment Reporting Information [Line Items]
Revenue	13,757	13,530
Rapid Assay Products [Member]
Segment Reporting Information [Line Items]
Revenue	43,086	43,637
Reference Laboratory Diagnostic And Consulting Services [Member]
Segment Reporting Information [Line Items]
Revenue	140,708	123,207
CAG Diagnostic Capital - Instruments [Member]
Segment Reporting Information [Line Items]
Revenue	22,974	20,113
Customer Information Managment and Diagnostic Imaging Systems [Member]
Segment Reporting Information [Line Items]
Revenue	29,155	25,652
CAG Segment [Member]
Segment Reporting Information [Line Items]
Revenue	357,639	324,531
Water Segment [Member]
Segment Reporting Information [Line Items]
Revenue	23,552	21,698
LPD Segment [Member]
Segment Reporting Information [Line Items]
Revenue	30,856	31,270
Other Segment [Member]
Segment Reporting Information [Line Items]
Revenue	$ 5,503	$ 4,978

Fair Value Measurements (Narrat

Fair Value Measurements (Narrative) (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Carrying value of long-term debt	$ 600,021	$ 597,085
Significant Other Observable Inputs (Level 2) [Member]
Long-term Debt, Fair Value	$ 612,000	$ 593,700

Fair Value Measurements (Schedu

Fair Value Measurements (Schedule Of Fair Value Of Assets And Liabilities Measured On Recurring Basis) (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	$ 217,617	$ 213,591
Agency Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	2,401	12,065
Corporate Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	152,378	177,613
Asset-backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	24,467
U.S. Government Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	17,068	12,871
Commercial Paper - Marketable Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	9,840	3,491
Certificates Of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	8,600	3,500
International Government Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	1,456	1,459
Municipal Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	1,407	1,399
Treasury Bills [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities		1,193
Measured At Fair Value On Recurring Basis [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	217,617	213,591
Measured At Fair Value On Recurring Basis [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	217,617	213,591
Measured At Fair Value On Recurring Basis [Member] | Equity Mutual Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Assets	2,207	2,264
Measured At Fair Value On Recurring Basis [Member] | Equity Mutual Funds [Member] | Quoted Prices In Active Markets For Identical Assets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Assets	2,207	2,264
Measured At Fair Value On Recurring Basis [Member] | Foreign Currency Exchange Contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Assets	2,556	4,876
Fair value of Liabilities	4,160	1,365
Measured At Fair Value On Recurring Basis [Member] | Foreign Currency Exchange Contracts [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Assets	2,556	4,876
Fair value of Liabilities	4,160	1,365
Measured At Fair Value On Recurring Basis [Member] | Deferred Compensation [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Liabilities	2,207	2,264
Measured At Fair Value On Recurring Basis [Member] | Deferred Compensation [Member] | Quoted Prices In Active Markets For Identical Assets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Liabilities	2,207	2,264
Measured At Fair Value On Recurring Basis [Member] | Interest Rate Swaps [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Liabilities	209	384
Measured At Fair Value On Recurring Basis [Member] | Interest Rate Swaps [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Liabilities	209	384
Measured At Fair Value On Recurring Basis [Member] | Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Assets	9,213	15,490
Measured At Fair Value On Recurring Basis [Member] | Money Market Funds [Member] | Quoted Prices In Active Markets For Identical Assets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Assets	9,213	15,490
Measured At Fair Value On Recurring Basis [Member] | Agency Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Assets		1,999
Measured At Fair Value On Recurring Basis [Member] | Agency Bonds [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Assets		1,999
Measured At Fair Value On Recurring Basis [Member] | Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Assets	2,299	1,800
Measured At Fair Value On Recurring Basis [Member] | Commercial Paper [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Assets	2,299	1,800
Measured At Fair Value On Recurring Basis [Member] | Corporate Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	152,378	177,613
Measured At Fair Value On Recurring Basis [Member] | Corporate Bonds [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	152,378	177,613
Measured At Fair Value On Recurring Basis [Member] | Asset-backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	24,467
Measured At Fair Value On Recurring Basis [Member] | Asset-backed Securities [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	24,467
Measured At Fair Value On Recurring Basis [Member] | U.S. Government Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	17,068	12,871
Measured At Fair Value On Recurring Basis [Member] | U.S. Government Bonds [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	17,068	12,871
Measured At Fair Value On Recurring Basis [Member] | Commercial Paper - Marketable Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	9,840	3,491
Measured At Fair Value On Recurring Basis [Member] | Commercial Paper - Marketable Securities [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	9,840	3,491
Measured At Fair Value On Recurring Basis [Member] | Certificates Of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	8,600	3,500
Measured At Fair Value On Recurring Basis [Member] | Certificates Of Deposit [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	8,600	3,500
Measured At Fair Value On Recurring Basis [Member] | Agency Bonds- Marketable Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	2,401	12,065
Measured At Fair Value On Recurring Basis [Member] | Agency Bonds- Marketable Securities [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	2,401	12,065
Measured At Fair Value On Recurring Basis [Member] | International Government Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	1,456	1,459
Measured At Fair Value On Recurring Basis [Member] | International Government Bonds [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	1,456	1,459
Measured At Fair Value On Recurring Basis [Member] | Municipal Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	1,407	1,399
Measured At Fair Value On Recurring Basis [Member] | Municipal Bonds [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	$ 1,407	1,399
Measured At Fair Value On Recurring Basis [Member] | Treasury Bills [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities		1,193
Measured At Fair Value On Recurring Basis [Member] | Treasury Bills [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities		$ 1,193

Hedging Instruments (Narrative)

Hedging Instruments (Narrative) (Details) $ in Thousands, € in Millions	3 Months Ended
	Mar. 31, 2016USD ($)	Mar. 31, 2016EUR (€)	Mar. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Derivative [Line Items]
Estimated net amount of losses expected to be reclassified out of accumulated other comprehensive income and into earnings within next 12 months	$ 1,000
General duration of foreign currency exchange contracts	24 months
Notional Amount of Foreign Currency Exchange Contracts			$ 204,300	$ 176,100
Unrealized gain on net investment hedge	$ 2,224
Series C Senior Note [Member]
Derivative [Line Items]
Notes Payable		€ 88.9	$ 100,000
Stated interest rate		1.785%	1.785%
Interest Rate Swap Effective On March 30, 2012 [Member]
Derivative [Line Items]
Fixed portion of interest rate associated with interest rate swap		1.36%	1.36%
Credit Facility borrowings hedged			$ 40,000
Interest Rate Swap Effective On March 28, 2013 [Member]
Derivative [Line Items]
Fixed portion of interest rate associated with interest rate swap		1.64%	1.64%
Credit Facility borrowings hedged			$ 40,000

Hedging Instruments (Schedule O

Hedging Instruments (Schedule Of Fair Values And Balance Sheet Classifications Of Derivatives Designated As Hedging Instruments) (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Derivatives, Fair Value [Line Items]
Hedging Liabilities, Total hedging instruments presented on the balance sheet	$ 104,991	$ 98,834
Hedging Liabilities, Gross amounts subject to master netting arrangements not offset on the balance sheet	1,809	1,268
Hedging Liabilities, Net amount	103,182	97,566
Cash Flow Hedges [Member]
Derivatives, Fair Value [Line Items]
Hedging Liabilities, Total hedging instruments presented on the balance sheet	4,369	1,749
Derivatives Designated As Hedging Instruments [Member]
Derivatives, Fair Value [Line Items]
Hedging Assets, Gross amounts subject to master netting arrangements not offset on the balance sheet	1,809	1,268
Hedging Assets, Net amount	747	3,608
Derivatives Designated As Hedging Instruments [Member] | Cash Flow Hedges [Member]
Derivatives, Fair Value [Line Items]
Hedging Assets, Total derivative instruments presented as cash flow hedges on the balance sheet	2,556	4,876
Foreign Currency Exchange Contracts [Member] | Accrued Liabilities [Member]
Derivatives, Fair Value [Line Items]
Hedging Liabilities, Total hedging instruments presented on the balance sheet	3,342	1,365
Foreign Currency Exchange Contracts [Member] | Other Long-Term Liabilities [Member]
Derivatives, Fair Value [Line Items]
Hedging Liabilities, Total hedging instruments presented on the balance sheet	818
Foreign Currency Exchange Contracts [Member] | Derivatives Designated As Hedging Instruments [Member] | Other Current Assets [Member]
Derivatives, Fair Value [Line Items]
Hedging Assets, Total derivative instruments presented as cash flow hedges on the balance sheet	2,482	4,876
Foreign Currency Exchange Contracts [Member] | Derivatives Designated As Hedging Instruments [Member] | Other Long-Term Assets [Member]
Derivatives, Fair Value [Line Items]
Hedging Assets, Total derivative instruments presented as cash flow hedges on the balance sheet	74
Interest Rate Swaps [Member] | Accrued Liabilities [Member]
Derivatives, Fair Value [Line Items]
Hedging Liabilities, Total hedging instruments presented on the balance sheet	209	384
Foreign Currency Borrowings Designated As Net Investment Hedge On The Balance Sheet [Member] | Long-term Debt [Member]
Derivatives, Fair Value [Line Items]
Hedging Liabilities, Total hedging instruments presented on the balance sheet	$ 100,622	$ 97,085

Hedging Instruments (Gain (Loss

Hedging Instruments (Gain (Loss) Recognized In Other Comprehensive Income On Derivative Instruments (Effective Portion)) (Details) - Derivatives Designated As Hedging Instruments [Member] - Cash Flow Hedges [Member] - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) Recognized in AOCI on Derivative Instruments (Effective Portion), Net of Tax	$ (3,695)	$ 4,221
Foreign Currency Exchange Contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) Recognized in AOCI on Derivative Instruments (Effective Portion), Net of Tax	(3,806)	4,179
Interest Rate Swaps [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) Recognized in AOCI on Derivative Instruments (Effective Portion), Net of Tax	$ 111	$ 42